High-Density Lipoprotein and Progression Rate of Atherosclerosis in Intravascular Ultrasound Trials

American Journal of Cardiology

Volumn 104, Issue 10 SUPPL., 2009, Pages 16E-21E

  Nicholls, Stephen J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; BEZAFIBRATE; C REACTIVE PROTEIN; CSL 111; ETC 216; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PIOGLITAZONE; RIMONABANT; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL FAT; ABDOMINAL OBESITY; ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTERY INTIMA; ARTERY WALL; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG MEGADOSE; DRUG SAFETY; HUMAN; INTRAVASCULAR ULTRASOUND; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ULTRASOUND TRANSDUCER; WAIST CIRCUMFERENCE;

EID: 71749112450     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.09.015     Document Type: Article

References (65)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
4. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto Jr. A.M., and AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
5. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E., and Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
6. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J., and West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
7. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
8. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs Jr. D.R., Bangdiwala S., and Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79 (1989) 8-15
9. Gordon D.J., and Rifkind B.M. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321 (1989) 1311-1316
10. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High-density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 62 (1977) 707-714
11. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., Kastelein J.J., Bittner V., and Fruchart J.C. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
12. Badimon J.J., Badimon L., Galvez A., Dische R., and Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 60 (1989) 455-461
13. Badimon J.J., Badimon L., and Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85 (1990) 1234-1241
14. Nicholls S.J., Cutri B., Worthley S.G., Kee P., Rye K.A., Bao S., and Barter P.J. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 25 (2005) 2416-2421
15. Plump A.S., Scott C.J., and Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Nat Acad Sci U S A 91 (1994) 9607-9611
16. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., and Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353 (1991) 265-267
17. Rong J.X., Li J., Reis E.D., Choudhury R.P., Dansky H.M., Elmalem V.I., Fallon J.T., Breslow J.L., and Fisher E.A. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 104 (2001) 2447-2452
18. Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Circulation 103 (2001) 3047-3050
19. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
20. Frick M.H., Elo O., Haapa K., Heinonen O.D., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., and Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
21. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J., and Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
22. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., Symeonidis A.N., Mercouris B.R., Pehlivanidis A., Bouloukos V.I., and Elisaf M. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 20 (2004) 627-637
23. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., Wolski K., Crowe T., Desai M.Y., Hazen S.L., Kapadia S.R., and Nissen S.E. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
24. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., and Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
25. Ballantyne C.M. Clinical trial endpoints: angiograms, events, and plaque instability. Am J Cardiol 82 (1998) 5M-11M
26. Brown B.G., Zhao X.-Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., and Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
27. Ericsson C.G., Hamsten A., Nilsson J., Grip L., Svane B., and de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996) 849-853
28. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
29. Chambless L.E., Heiss G., Folsom A.R., Rosamond W., Szklo M., Sharrett A.R., and Clegg L.X. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 146 (1997) 483-494
30. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., and Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007) 459-467
31. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
32. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 22 (2006) 2243-2250
33. Rye K.A., and Barter P.J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 24 (2004) 421-428
34. Angelin B., Parini P., and Eriksson M. Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL. Atheroscler Suppl 3 (2002) 23-30
35. Bisoendial R.J., Hovingh G.K., Levels J.H.M., Lerch P.G., Andresen I., Hayden M.R., Kastelein J.J.P., and Stroes E.S.G. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107 (2003) 2944-2948
36. Spieker L.E., Sudano I., Hurlimann D., Lerch P.G., Lang M.G., Binggeli C., Corti R., Ruschitzka F., Luscher T.F., and Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (2002) 1399-1402
37. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., Eaton G.M., Lauer M.A., Sheldon W.S., Grines C.L., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
38. Nicholls S.J., Tuzcu E.M., Sipahi I., Schoenhagen P., Crowe T., Kapadia S.R., and Nissen S.E. Relationship between atheroma regression and change in lumen size following infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 47 (2006) 992-997
39. Shah P.K., Nilsson J., Kaul S., Fishbein M.C., Ageland H., Hamsten A., Johansson J., Karpe F., and Cercek B. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97 (1998) 780-785
40. Tardif J.C., Gregoire J., L'Allier P.L., Ibrahim R., Lesperance J., Heinonen T.M., Kouz S., Berry C., Basser R., Lavoie M.A., Guertin M.C., and Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007) 1675-1682
41. Sacks F.M., Rudel L.L., Conner A., Akeefe H., Kostner G., Baki T., Rothblat G., de la Llera-Moya M., Asztalos B., Perlman T., et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res 50 (2009) 894-907
42. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., Davignon J., Erbel R., Fruchart J.C., Tardif J.C., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
43. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., Grines C.L., and DeMaria A.N. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
44. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O'Shaughnessy C., and Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
45. Ballantyne C.M., Raichlen J.S., Nicholls S.J., Erbel R., Tardif J.C., Brener S.J., Cain V.A., and Nissen S.E. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 117 (2008) 2458-2466
46. Barter P.J., Chapman M.J., Hennekens C.H., Rader D.J., and Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 160-167
47. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., and Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (2000) 203-207
48. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., Pettey C.L., Adari H., Hammond R.A., Beattie D.T., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 20 (2000) 2106-2112
49. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., Lopez-Sendon J., Mosca L., Tardif J.C., Waters D.D., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
50. Nissen S.E., Tardif J.C., Nicholls S.J., Revkin J.H., Shear C.L., Duggan W.T., Ruzyllo W., Bachinsky W.B., Lasala G.P., and Tuzcu E.M. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
51. Bots M.L., Visseren F.L., Evans G.W., Riley W.A., Revkin J.H., Tegeler C.H., Shear C.L., Duggan W.T., Vicari R.M., Grobbee D.E., and Kastelein J.J. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370 (2007) 153-160
52. Kastelein J.J., van Leuven S.I., Burgess L., Evans G.W., Kuivenhoven J.A., Barter P.J., Revkin J.H., Grobbee D.E., Riley W.A., Shear C.L., Duggan W.T., and Bots M.L. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
53. Nicholls S.J., Tuzcu E.M., Brennan D.M., Tardif J.C., and Nissen S.E. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118 (2008) 2506-2514
54. Tall A.R., Yvan-Charvet L., and Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 27 (2007) 257-260
55. Vergeer M., Bots M.L., van Leuven S.I., Basart D.C., Sjibrands E.J., Evans G.W., Grobbee D.E., Visseren F.L., Stalenhoef A.F., Stroes E.S., and Kastelein J.J. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118 (2008) 2515-2522
56. Forrest M.J., Bloomfield D., Briscoe R.J., Brown P.N., Cumiskey A.M., Ehrhart J., Hershey J.C., Keller W.J., Ma X., McPherson H.E., et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154 (2008) 1465-1473
57. Stein E.A., Stroes E., Steiner G., Buckley B., Capponi A., Burgess T., Niesor E., Kallend D., and Kastelein J.J. Safety and tolerability of dalcetrapib. J Am Coll Cardiol 51 (2008) A333
58. Bloomfield D., Carlson G.L., Sapre A., Tribble D., McKenney J.M., Littlejohn III T.W., Sisk C.M., Mitchel Y., and Pasternak R.C. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 157 (2009) 352-360
59. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., Jure H., De Larochelliere R., Staniloae C.S., Mavromatis K., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008) 1561-1573
60. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino RB S., Perez A., Provost J.C., and Haffner S.M. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
61. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
62. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
63. Nicholls S.J., Bayturan O., Hu T., Kupfer S., Perez A., Menon V., Askari A., Srinivas V.S., Nesto R.W., Tuzcu E.M., and Nissen S.E. Lowering of the triglyceride/HDL cholesterol ratio predicts the benefit of pioglitazone on progression of coronary atherosclerosis in diabetic patients. Circulation 118 (2008) S_1135
64. Davidson M., Meyer P.M., Haffner S., Feinstein S., D'Agostino R S., Kondos G.T., Perez A., Chen Z., and Mazzone T. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 117 (2008) 2123-2130
65. Nissen S.E., Nicholls S.J., Wolski K., Rodes-Cabau J., Cannon C.P., Deanfield J.E., Despres J.P., Kastelein J.J., Steinhubl S.R., Kapadia S., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299 (2008) 1547-1560